Citadel Advisors’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,920
| Closed | -$16K | – | 14821 |
|
|
2022
Q1 | $16K | Sell |
1,920
-3,305
| -63% | -$33.8K | ﹤0.01% | 13310 |
|
|
2021
Q4 | $70K | Sell |
5,225
-1,500
| -22% | -$37.7K | ﹤0.01% | 13035 |
|
|
2021
Q3 | $293K | Buy |
6,725
+970
| +17% | +$41.8K | ﹤0.01% | 11108 |
|
|
2021
Q2 | $241K | Sell |
5,755
-1,655
| -22% | -$72.7K | ﹤0.01% | 11778 |
|
|
2021
Q1 | $359K | Sell |
7,410
-3,620
| -33% | -$211K | ﹤0.01% | 10435 |
|
|
2020
Q4 | $1.08M | Buy |
11,030
+9,560
| +650% | +$838K | ﹤0.01% | 6644 |
|
|
2020
Q3 | $101K | Buy |
1,470
+380
| +35% | +$33.2K | ﹤0.01% | 9274 |
|
|
2020
Q2 | $115K | Buy |
+1,090
| New | +$129K | ﹤0.01% | 8917 |
|
|
2018
Q4 | – | Sell |
-1,150
| Closed | -$121K | – | 10008 |
|
|
2018
Q3 | $121K | Buy |
+1,150
| New | +$110K | ﹤0.01% | 8492 |
|
|
2018
Q2 | – | Sell |
-770
| Closed | -$97K | – | 9458 |
|
|
2018
Q1 | $97K | Sell |
770
-70
| -8% | -$10.9K | ﹤0.01% | 7726 |
|
|
2017
Q4 | $140K | Buy |
840
+135
| +19% | +$34.6K | ﹤0.01% | 7303 |
|
|
2017
Q3 | $222K | Buy |
+705
| New | +$222K | ﹤0.01% | 6539 |
|
|
2017
Q2 | – | Sell |
-915
| Closed | -$211K | – | 8279 |
|
|
2017
Q1 | $211K | Buy |
+915
| New | +$158K | ﹤0.01% | 6426 |
|
|
2016
Q1 | – | Sell |
-40
| Closed | -$6K | – | 8367 |
|
|
2015
Q4 | $6K | Buy |
+40
| New | +$6K | ﹤0.01% | 8419 |
|
Other funds holding CALA
Citadel Advisors's CALA Position: Q1 2023 in Review
Citadel Advisors sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 199,269 shares — an estimated $650K sold.
Citadel Advisors first reported a position in CALA in Q3 2015 and held it in 24 quarters. The position peaked at $8.48M in Q2 2017. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- Citadel Advisors reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 199,269 Calithera Biosciences, Inc shares in Q1 2023, an estimated $650K.
- Citadel Advisors first reported a position in Calithera Biosciences, Inc in Q3 2015 and held it in 24 quarters.
- Citadel Advisors's Calithera Biosciences, Inc position peaked at $8.48M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.